Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Molecular Partners
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
June 14, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
June 11, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
June 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
May 16, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supporting MP0533’s Proposed Mechanism of Action
April 29, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Life Science Cares Launches in Switzerland
April 19, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
April 17, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2024
March 26, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
March 14, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Dismissal of Class Action Lawsuit
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
March 01, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
January 07, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
January 05, 2024
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
December 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
December 10, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
November 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
November 03, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
November 02, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
November 01, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
October 26, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
September 13, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
August 24, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
June 27, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
June 19, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
May 25, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
May 16, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
May 11, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
April 14, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
April 04, 2023
From
Molecular Partners
Via
GlobeNewswire
Tickers
MOLN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.